



## Kymera Therapeutics to Participate in Upcoming September Investor Conferences

August 28, 2023

WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- [Kymera Therapeutics, Inc.](#) (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company's management team will attend and participate in presentations at the following upcoming investor events:

- Wells Fargo 2023 Healthcare Conference in Boston, MA on September 6 at 8:45 a.m. ET;
- Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on September 12 at 4:15 p.m. ET; and
- H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on September 13 at 10:00 a.m. ET.

Live webcasts of the presentations will be available under the "Events and Presentations" section of the [Investors](#) page on the Company's website at [www.kymeratx.com](#). A replay of the webcast will be archived and available following the event.

### About Kymera Therapeutics

Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera's Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most promising targets and provide patients with more effective treatments. Kymera's initial programs target IRAK4, IRAK1MiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a "Fierce 15" company by Fierce Biotech and has been recognized by both the Boston Globe and the Boston Business Journal as one of Boston's top workplaces. For more information about our people, science and pipeline, please visit [www.kymeratx.com](#) or follow us on [Twitter](#) or [LinkedIn](#).

### Investor Contact:

Justine Koenigsberg  
Vice President, Investor Relations  
[investors@kymeratx.com](mailto:investors@kymeratx.com)  
857-285-5300

### Media Contact:

Todd Cooper  
Senior Vice President, Corporate Affairs  
[media@kymeratx.com](mailto:media@kymeratx.com)  
857-285-5300